West Pharmaceutical Services, Inc. $WST Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 55.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,263 shares of the medical instruments supplier’s stock after selling 1,547 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in West Pharmaceutical Services were worth $276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of WST. Allworth Financial LP boosted its stake in shares of West Pharmaceutical Services by 229.7% in the 1st quarter. Allworth Financial LP now owns 455 shares of the medical instruments supplier’s stock valued at $96,000 after buying an additional 317 shares during the period. Ballentine Partners LLC raised its holdings in shares of West Pharmaceutical Services by 49.4% in the 1st quarter. Ballentine Partners LLC now owns 1,346 shares of the medical instruments supplier’s stock valued at $301,000 after purchasing an additional 445 shares in the last quarter. Signaturefd LLC grew its stake in shares of West Pharmaceutical Services by 14.2% during the first quarter. Signaturefd LLC now owns 1,119 shares of the medical instruments supplier’s stock worth $251,000 after purchasing an additional 139 shares in the last quarter. Apollon Wealth Management LLC increased its holdings in West Pharmaceutical Services by 10.5% in the first quarter. Apollon Wealth Management LLC now owns 1,321 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 126 shares during the last quarter. Finally, Dakota Wealth Management raised its stake in West Pharmaceutical Services by 37.6% in the first quarter. Dakota Wealth Management now owns 2,839 shares of the medical instruments supplier’s stock valued at $636,000 after buying an additional 776 shares in the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 0.1%

Shares of West Pharmaceutical Services stock opened at $273.66 on Thursday. The company has a 50-day moving average of $268.13 and a two-hundred day moving average of $241.08. West Pharmaceutical Services, Inc. has a 12-month low of $187.43 and a 12-month high of $348.90. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The stock has a market cap of $19.69 billion, a PE ratio of 40.43, a price-to-earnings-growth ratio of 4.09 and a beta of 1.08.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.29. The firm had revenue of $804.60 million during the quarter, compared to the consensus estimate of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.West Pharmaceutical Services’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the business posted $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on WST shares. Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. UBS Group raised their price objective on West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, October 24th. Redburn Partners set a $311.00 target price on West Pharmaceutical Services in a report on Monday, September 15th. Finally, Rothschild & Co Redburn assumed coverage on West Pharmaceutical Services in a research report on Monday, September 15th. They set a “buy” rating and a $311.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $349.20.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.